Tag: pharmaceuticals

AbCellera Launches $200 Million Stock Offering, Pulling Shares Down After 44% Surge

AbCellera Biologics shares reversed after the company launched a $200 million public offering, unwinding a 44% rally driven by its hot flash treatment prog

Vertex Shares Climb as Rival Sionna’s Cystic Fibrosis Drug Fails Key Trial

Vertex Pharmaceuticals shares surged after rival Sionna Therapeutics saw its stock plunge roughly 90% on a failed cystic fibrosis drug trial.

Bristol Myers Squibb to Build $2.3 Billion Manufacturing Campus in Houston, Texas

Bristol Myers Squibb will build a $2.3 billion manufacturing campus in Houston, adding jobs and expanding its US production capacity amid an onshoring push

Pfizer Beats Quarterly Estimates on Strong Non-Covid Sales, Lifts Revenue Floor

Pfizer topped quarterly profit and revenue estimates on strong Eliquis demand, raising its revenue floor while cutting Covid product forecasts to $4 billio

Eli Lilly Tops Estimates and Lifts Outlook as GLP-1 Drug Sales Surge

Eli Lilly beat quarterly estimates and lifted its 2026 revenue outlook to $85-$87 billion as Mounjaro and Zepbound sales surged 48%.

Pfizer Beats Profit Estimates, Targets $2.5 Billion in Fresh Cost Cuts

Pfizer topped quarterly profit forecasts and raised its 2026 guidance while targeting an additional $2.5 billion in cost reductions amid falling Covid sale

Merck Lifts Revenue Outlook on Strong Drug Sales but Trims Profit Forecast

Merck lifted its revenue outlook on strong new drug sales but trimmed its profit forecast to absorb charges tied to its Terns Pharmaceuticals acquisition.

AstraZeneca in Talks to Acquire Bristol Myers Squibb in Near-$400 Billion Merger

AstraZeneca is in discussions to acquire Bristol Myers Squibb in a near-$400 billion merger that would create the world's fourth-largest drugmaker.

Novo Nordisk Shares Sink 10% After Heart Drug Ziltivekimab Fails Late-Stage Trial

Novo Nordisk shares fell about 10% after its experimental heart medicine ziltivekimab missed the primary goal of a key late-stage trial.

Regeneron Shares Climb as Eczema Drug Dupixent Powers Quarterly Earnings Beat

Regeneron Pharmaceuticals shares climbed after quarterly results topped estimates, powered by strong sales of its eczema drug Dupixent.

Argenx Agrees $2.2 Billion Acquisition of Forte Biosciences to Bolster Autoimmune Pipeline

Argenx has agreed to acquire Forte Biosciences for about $2.2 billion to strengthen its autoimmune drug pipeline, sending Forte shares up roughly 39%.

AstraZeneca Chief Urges Western Drugmakers to Match ‘Chinese Speed’ as Shares Rise

AstraZeneca CEO Pascal Soriot warns Western drugmakers risk falling behind faster Chinese rivals as the company's shares rise ahead of earnings.

- A word from our sponsors -

spot_img

Follow us

HomeTagsPharmaceuticals